Previous 10 | Next 10 |
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
2023-12-19 17:03:56 ET More on Anavex Life Sciences How Soon Might Anavex's Alzheimer's Drug Be Approved? The Good/Bad News Anavex Life Sciences: Rett Safety Dance With Broader CNS Implications (Rating Downgrade) t Anavex Life Sciences falls after Q4 pipeline upd...
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders,...
2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...
2023-11-29 07:21:25 ET Summary The EU recommends Anavex proceed with a full approval application for Alzheimer's drug Blarcamesine based on full Phase 2b/3 trial data. The U.S. FDA may grant accelerated approval to Anavex's Blarcamesine based on biomarker data alone. Blarcamesine ...
2023-11-27 20:52:36 ET Summary ANAVEX2-73 Safety Follow-Up: Extended safety follow-up for Rett syndrome raises concerns but shows commitment to patient safety and scientific rigor. Financial Health: Anavex demonstrates robust short-term liquidity; however, increasing accumulated d...
2023-11-27 12:10:46 ET More on Anavex Life Sciences Anavex Life Sciences Corp. (AVXL) Q4 2023 Earnings Call Transcript Anavex Alzheimer's And Parkinson's Drug Underappreciated By Investors Anavex: The September Data Anavex gains as EU filing for Alzheimer...
2023-11-27 09:52:06 ET Anavex Life Sciences Corp. (AVXL) Q4 2023 Earnings Call Transcript November 27, 2023 08:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conferen...
2023-11-27 08:02:06 ET More on Anavex Life Sciences Anavex Alzheimer's And Parkinson's Drug Underappreciated By Investors Anavex: The September Data Anavex: Additional P2b/3 Alzheimer's Trial Data Raises Additional Questions Anavex gains as EU filing for Alzh...
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) shares. Investors, who purchased Anavex Life Sciences Corp. (NASDAQ: AVXL) shares prior to Februa...